FAP and neoplasm: Agents like αFAP-PE38 and radiolabeled antibodies (e.g., 177Lu-ESC11, 177Lu-ESC14) have shown the ability to deplete FAP+ stroma and suppress tumor growth in preclinical models [129,130].